Division of Infectious Diseases, Department of Internal Medicine, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas.
Department of Neuroscience and Department of Neurology, University of Rochester School of Medicine, Rochester, New York.
J Med Virol. 2018 Jan;90(1):26-33. doi: 10.1002/jmv.24917. Epub 2017 Sep 26.
Both respiratory syncytial virus (RSV) and influenza A virus (IAV) may infect human peripheral blood mononuclear leukocytes (PBMC) during the immune response to viral challenge as the cells are recruited to the respiratory tract. The current studies demonstrated differences in PBMC responses to the two viruses very early after exposure, including reduced fos protein and CD69 expression and IL-2 production by RSV-exposed T lymphocytes. Exposure to RSV resulted in reduced lymphocyte proliferation despite evidence of a virus-specific T lymphocyte frequency equivalent to that for influenza virus. Reduced RSV-induced proliferation was not due to apoptosis, which was itself reduced relative to that of influenza virus-exposed T lymphocytes. The data indicate that differential immune responses to RSV and influenza virus are determined early after exposure of human PBMC and support the concept that the anamnestic immune response that might prevent clinically evident reinfection is attenuated very soon after exposure to RSV. Thus, candidate RSV vaccines should be expected to reduce but not prevent clinical illness upon subsequent infection by RSV. Furthermore, effective therapeutic agents for RSV are likely to be needed, especially for high-risk populations, even after vaccine development.
呼吸道合胞病毒(RSV)和甲型流感病毒(IAV)都可能在病毒挑战引起的免疫反应期间感染人外周血单个核细胞(PBMC),因为这些细胞被募集到呼吸道。目前的研究表明,在接触病毒后的早期,PBMC 对这两种病毒的反应存在差异,包括 RSV 暴露的 T 淋巴细胞中 fos 蛋白和 CD69 表达以及 IL-2 产生减少。尽管存在与流感病毒相当的病毒特异性 T 淋巴细胞频率的证据,但 RSV 暴露导致淋巴细胞增殖减少。RSV 诱导的增殖减少不是由于细胞凋亡所致,而细胞凋亡本身相对于流感病毒暴露的 T 淋巴细胞减少。这些数据表明,对 RSV 和流感病毒的不同免疫反应是在 PBMC 暴露后的早期确定的,并支持这样的概念,即在 RSV 暴露后不久,可能预防临床明显再感染的回忆性免疫反应就会减弱。因此,预期 RSV 候选疫苗在随后的 RSV 感染时会减少但不能预防临床疾病。此外,即使在疫苗开发之后,也可能需要针对 RSV 的有效治疗药物,尤其是针对高危人群。